Archive · 5 Oct 2026
Four Pharma Stocks in Focus After Company Updates
Four pharmaceutical companies have updates that may draw investors’ attention.
Maharashtra FDA cancelled Cipla’s licence for selling and distributing medicines from its Pune warehouse.
The regulator cited irregularities and concerns about the labeling of one medicine.
Cipla says its warehouse follows the rules and that it is reviewing the decision.
Sun Pharmaceutical Industries shared results about a medicine for severe hair loss.
It said nearly 94% of patients who responded after one year still had a response after two years.
Piramal Pharma’s sales-support agreement with Bayer Pharma will end in 2026 and will not be renewed.
Aurobindo Pharma subsidiary Apitoria Pharma is involved in acquiring a contract research business.
Cipla’s wholesale drug sale and distribution licence in Pune was cancelled by Maharashtra FDA over regulatory and storage-related irregularities.
Maharashtra FDA also raised concerns about the misbranding of Cipla’s Reactin Plus Tablets; Cipla disputes the decision and is reviewing its options.
Sun Pharmaceutical Industries reported that nearly 94% of LEQSELVI responders at Week 52 maintained their response through Week 108.
Piramal Pharma said its Bayer Pharma commercial agreement will end on December 31, 2026, and its non-renewal is not expected to materially affect the company.
Apitoria Pharma is acquiring A1 Biochem Group’s Contract Research Services business, including a US-based company that will become a step-down subsidiary.
- Who
- Cipla, Sun Pharmaceutical Industries, Piramal Pharma, and Apitoria Pharma, a subsidiary of Aurobindo Pharma.
- What
- Four company developments involving a cancelled licence, clinical data, an expiring commercial agreement, and a contract research business acquisition.
- When
- The updates were expected to put the stocks in focus on Monday, October 5; the year is not specified. Piramal Pharma’s agreement ends December 31, 2026.
- Where
- The licence decision concerns Cipla’s Pune warehouse; the acquired A1 Biochem Labs LLC is based in the United States.
- Why
- The updates concern regulatory action, clinical trial results, a commercial agreement ending, and a business acquisition.
Regulator’s position
Cipla’s position
Pune licence cancellation
Regulator’s position
Maharashtra FDA cited regulatory and storage-related irregularities in cancelling Cipla’s wholesale drug sale and distribution licence.
Cipla’s position
Cipla said its Pune warehouse complies with applicable requirements, expressed disappointment with the decision, and is reviewing the order and its options.
Reactin Plus labeling
Regulator’s position
Maharashtra FDA raised concerns about misbranding of Reactin Plus Tablets.
Cipla’s position
Cipla said it is reviewing the regulator’s order; the report does not provide a separate detailed response about the misbranding concern.
- Cipla licence
- Maharashtra FDA cancelled the wholesale drug sale and distribution licence for Cipla’s Pune site.
- Cipla response
- Cipla said it was disappointed, maintains the warehouse complies with applicable requirements, and is reviewing the order.
- LEQSELVI result
- Nearly 94% of patients who responded at Week 52 maintained their response through Week 108.
- LEQSELVI presentations
- New data were featured in seven presentations at the 2026 EADV Congress.
- Piramal agreement
- The Bayer Pharma commercial agreement expires December 31, 2026, and will not be renewed.
- Piramal revenue share
- The agreement contributed commission income and represented less than 5% of consolidated revenue.
- A1 Biochem transaction
- A1 Biochem USA completed the acquisition of 100% of US-based A1 Biochem Labs LLC, which will become a step-down subsidiary of A1 Biochem Labs India.